362 related articles for article (PubMed ID: 23950184)
1. High doses of infliximab in the management of juvenile idiopathic arthritis.
Tambralli A; Beukelman T; Weiser P; Atkinson TP; Cron RQ; Stoll ML
J Rheumatol; 2013 Oct; 40(10):1749-55. PubMed ID: 23950184
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
4. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years.
Aeschlimann FA; Hofer KD; Cannizzaro Schneider E; Schroeder S; Lauener R; Saurenmann RK
J Rheumatol; 2014 Jul; 41(7):1409-15. PubMed ID: 24833759
[TBL] [Abstract][Full Text] [Related]
5. [Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy].
De Marco G; Gerloni V; Pontikaki I; Luriati A; Teruzzi B; Salmaso A; Valcamonica E; Gattinara M; Fantini F
Reumatismo; 2007; 59(1):50-6. PubMed ID: 17435842
[TBL] [Abstract][Full Text] [Related]
6. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.
Ruperto N; Lovell DJ; Cuttica R; Woo P; Meiorin S; Wouters C; Silverman ED; Balogh Z; Henrickson M; Davidson J; Foeldvari I; Imundo L; Simonini G; Oppermann J; Xu S; Shen YK; Visvanathan S; Fasanmade A; Mendelsohn A; Martini A; Giannini EH; ;
Ann Rheum Dis; 2010 Apr; 69(4):718-22. PubMed ID: 20237125
[TBL] [Abstract][Full Text] [Related]
9. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study.
Aeschlimann FA; Angst F; Hofer KD; Cannizzaro Schneider E; Schroeder-Kohler S; Lauener R; van der Kleij D; Rispens T; Saurenmann RK
J Rheumatol; 2017 Mar; 44(3):334-341. PubMed ID: 28089968
[TBL] [Abstract][Full Text] [Related]
11. Children with juvenile idiopathic arthritis frequently experience interruptions to their medical therapy.
Kazamia K; Holmquist L; Fagerlund A; Berntson L
Acta Paediatr; 2014 May; 103(5):529-36. PubMed ID: 24517256
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis.
Norambuena R X; Mallol J; Ríos M G; Quevedo R F; Quezada L A
Allergol Immunopathol (Madr); 2007; 35(2):52-6. PubMed ID: 17428400
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
14. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
Tarkiainen M; Tynjälä P; Vähäsalo P; Kröger L; Aalto K; Lahdenne P
Pediatr Rheumatol Online J; 2019 Dec; 17(1):80. PubMed ID: 31842940
[TBL] [Abstract][Full Text] [Related]
16. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
[TBL] [Abstract][Full Text] [Related]
18. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
19. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
Ruperto N; Lovell DJ; Cuttica R; Wilkinson N; Woo P; Espada G; Wouters C; Silverman ED; Balogh Z; Henrickson M; Apaz MT; Baildam E; Fasth A; Gerloni V; Lahdenne P; Prieur AM; Ravelli A; Saurenmann RK; Gamir ML; Wulffraat N; Marodi L; Petty RE; Joos R; Zulian F; McCurdy D; Myones BL; Nagy K; Reuman P; Szer I; Travers S; Beutler A; Keenan G; Clark J; Visvanathan S; Fasanmade A; Raychaudhuri A; Mendelsohn A; Martini A; Giannini EH; ;
Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
